Generac's Q3 earnings miss and reduced 2025 sales and margin guidance send shares tumbling, despite long-term growth drivers remaining intact.
FDA issues draft guidance to streamline biosimilar approvals, aiming to cut bureaucracy and increase competition for lower-cost biologics.
Prop 50 aims to reshape California's congressional map, sparking debate over partisan gerrymandering and the future of the state's House representation.
Generac's Q3 earnings miss and reduced 2025 sales and margin guidance send shares tumbling, despite long-term growth drivers remaining intact.
FDA issues draft guidance to streamline biosimilar approvals, aiming to cut bureaucracy and increase competition for lower-cost biologics.
Prop 50 aims to reshape California's congressional map, sparking debate over partisan gerrymandering and the future of the state's House representation.